Bioethics, Ltd.
BOTH
Other OTC0.01
USD
- -
- -
CIK
0000894560
ISIN
US09059E2090
CUSIP
09059E209
Return %
Stock
S&P500
1Y
-99.59
18.21
3Y
-99.57
63.29
5Y
-99.74
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Mark A. Scharmann
- Full Time Employees
- 1
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 1661 Lakeview Circle Ogden UT United States of America 84403
- IPO Date
- Jun 27, 2002
- CIK
- 0000894560
- Similar Companies
- Business
- Bioethics Ltd. (BOTH) is a shell company that conducts no active business operations and focuses on seeking merger, acquisition, or business combination opportunities. Founded in 1990 and headquartered in Ogden, UT, the company currently generates no revenue and employs one person while traded on the OTC market. In September 2024, Bioethics entered into an agreement and plan of merger with SILQ Technologies Corporation via a reverse triangular merger, under which a newly formed subsidiary of Bioethics merges with SILQ, with SILQ surviving as a wholly owned subsidiary; all outstanding SILQ shares convert into Bioethics common and preferred stock, post-merger SILQ stockholders to own approximately 89% of Bioethics on a fully diluted basis, alongside a planned 1-for-2 reverse stock split and a targeted $5.5 million private placement to fund operations and debt reduction, though the transaction remains subject to SILQ shareholder approval, capital raise completion within 90 days, and other closing conditions with no assurances of consummation. Upon closing, Bioethics intends to leverage SILQ's patented chemical coating technology, spun out of UCLA in 2017, which deposits permanent surface treatments on plastics and elastomers to provide bacterial resistance, reduced inflammation, anti-clotting properties, biofouling reduction, and enhanced lubricity for medical devices, industrial, and commercial applications; SILQ's initial FDA-cleared product is the ClearTract Foley Catheter, supported by an Innovative Technology contract from Vizient, Inc. for access to over 5,000 U.S. hospitals, with plans for additional medical devices and turnkey coating services targeting implantable device makers, water purification, beverage processing, and pharmaceutical production. The company's board includes recent addition Douglas Morris as director since April 2024.